An interventional study of Exercise training in Coronary Artery Disease and Atherosclerosis, sponsored by Instituto Nacional de Cardiologia de Laranjeiras. Recruiting at 1 site in Brazil. Open to participants aged 40 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Instituto Nacional de Cardiologia de Laranjeiras · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 152 studies in Coronary Artery Disease with a site in Brazil — 22 open to participants now, 29 under way, 4 of them phase 3. Coronary Artery Disease · Brazil.
Among the 152 studies in Coronary Artery Disease with a site in Brazil, this one is the 90th largest by planned enrollment of the 123 interventional ones that give a count, is one of 6 that started in 2024, is one of 67 with no phase, reaches primary completion later than 13 of the 28 other live ones, and was the 138th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →22 of the 152 studies in Coronary Artery Disease with a site in Brazil are open now. Recruiting first, the newest first:
Scitech Produtos Medicos SA · Sites in Brazil
Ages 18+
InCor Heart Institute · Sites in Brazil
Ages 45–70 · Women only
University of Sao Paulo General Hospital · Sites in Brazil
Ages 46–69 · Men only
University of Sao Paulo General Hospital · Sites in Brazil
Ages 50–80 · Healthy volunteers
Federal University of São Paulo · Sites in Brazil
Ages 18–80 · Healthy volunteers
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 40 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
152 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 17 · Phase 3 25 · Phase 4 17
First in 1999; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 100 across the 123 interventional studies, 740 across the 28 observational. Of the 93 that completed or were terminated, 15 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 152 have an industry lead sponsor. The 10 most frequent:
Instituto Nacional de Cardiologia de Laranjeiras is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Instituto Nacional de Cardiologia de Laranjeiras has 1 study filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
3 of the studies in Coronary Artery Disease with a site in Brazil that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06579807Instituto Nacional de Cardiologia de LaranjeirasCardiac Rehabilitation and Coronary Artery Disease | 2026-12-31 |
| NCT07699679Federal University of São PauloPhotobiomodulation in Coronary Artery Bypass Grafting With No-Touch vs Conventional Saphenous Vein Harvesting. | 2027-08 |
| NCT07734831University of the State of Santa CatarinaTELEREHAB-BR: Cardiovascular Rehabilitation Models Trial | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 152 studies in Coronary Artery Disease with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients with coronary artery disease (CAD) aged 40-70 years will undergo exercise training (thrice weekly for 12 weeks). A reference group composed of healthy individuals will be included. Evaluations will be conducted at baseline and after the intervention period during two visits. During the first visit, carotid artery thickness will be assessed via ultrasound before and after a cardiopulmonary exercise testing. The second visit will include the evaluation of endothelial function using venous occlusion plethysmography. After this, participants will engage in 30 minutes of moderate-intensity aerobic exercise, and blood samples will be collected pre- and post-exercise. Circulating levels of kynurenine pathway (KP) metabolites (Tryptophan, kynurenine, kynurenic acid, and quinolinic acid), pro-inflammatory cytokines, cell adhesion molecules, and lipid profiles will be measured via Enzyme-Linked Immunosorbent Assay (ELISA), multiplex essays, and biochemical analysis; respectively.
Participants and recruitment: In this clinical trial, 28 patients with CAD will be enrolled from the Pedro Ernesto University Hospital (HUPE) and 22 control volunteers without evidence of CAD (CTL) will be randomly recruited from among employees and students at the University of Rio de Janeiro State (UERJ). The groups will be matched by age and habitual physical activity level, assessed by the Baecke questionnaire, which quantifies activities performed at home, work, and leisure (sports).
All participants will receive oral and written instructions regarding the risks and benefits of the study and will provide written informed consent. The study was approved by the Research Ethics Committee of HUPE (CAAE 81718324.3.0000.5259). The study also adheres to SPIRIT 2013 (Standard Protocol Items: Recommendations for International Trials).
Study design: Evaluations will be conducted at baseline and after the 12-week intervention period during two visits interspersed by at least 72-hours interval. Outcomes in the CTL group will be assessed only at baseline to provide reference values. Visits will take place at the Physical Activity and Health Promotion Laboratory (LABSAU) and the Clinical and Experimental Research Laboratory on Vascular Biology (BioVasc), always in the morning (8:00 - 11:00 am), in rooms with controlled temperatures between 22°-24°C and relative humidity between 60-70%. Participants will be instructed to avoid physical activity, alcohol, and stimulants 48 hours prior to assessments.
During the first visit, volunteers will undergo a medical history assessment. If eligible, they will read and sign the informed consent form, if they agree to participate. Subsequently, carotid intima-media thickness will be assessed via carotid ultrasound, followed by a cardiopulmonary exercise testing (CPET). Immediately after the test, carotid intima-media thickness will be reassessed.
On the second visit, patients will undergo blood collection after 8 hours of fasting, followed by an assessment of vascular function using venous occlusion plethysmography. Approximately 15 min after a light standardized breakfast, participants will engage in 30 minutes of moderate-intensity aerobic exercise, after which blood samples will be collected again.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The multimodal supervised exercise program will include aerobic, resistance, and flexibility exercises during 12 weeks, performed in 3 weekly sessions lasting 60 minutes each.
Behavioral: Exercise training
A reference group composed of healthy individuals without intervention will be included.
The multimodal supervised exercise program will include aerobic, resistance, and flexibility exercises. The training program will last 12 weeks, performed in 3 weekly sessions lasting 60 minutes each. Aerobic exercise, lasting between 20-30 minutes, will be conducted on a treadmill or stationary bike at an intensity ranging from 75-85% of the maximal heart rate (HR), based on the cardiopulmonary exercise testing. Resistance training, lasting 30 minutes, will include 8 to 10 exercises performed in 3 sets of 10 to 12 maximum repetitions with 1-minute intervals, targeting major muscle groups of the upper and lower limbs, with loads corresponding to 80-90% of the 10-repetitions maximum (RM).
Carotid intima-media thickness
The assessment of the intima-media thickness (IMT) of the left and right common carotid arteries will be performed with the patient in the supine position, with the head turned to the side (45°), using a portable ultrasound device (Logiq-e, GE HealthCare, Boston, MA, USA) with a 9 L linear probe (12 MHz).
Time frame: Baseline and 12 weeks
Blood biomarkers of kynurenine pathway metabolites
Plasma levels of KP metabolites \[tryptophan (TRP), kynurenine (KYN), quinolinic acid (QUINA), and kynurenic acid (KYNA)\], will be measured using commercially available Enzyme-Linked Immunosorbent Assay (ELISA) kits.
Time frame: Baseline and 12 weeks
Blood biomarkers of inflammation
Pro-inflammatory cytokines \[interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interferon-gamma (IFN-y)\] will be measured using commercially available Enzyme-Linked Immunosorbent Assay (ELISA) kits.
Time frame: Baseline and 12 weeks
Blood biomarkers of endothelial injury
Plasma levels of soluble P-selectin, vascular cell adhesion molecule-1 (sVCAM-1), and intercellular adhesion molecule-1 (sICAM-1) will be assessed using the Human Cardiovascular Disease Panel 2 magnetic kit (EMD Millipore Corporation, MA, USA), with a sensitivity greater than 0.079 ng/ml.
Time frame: Baseline and 12 weeks
Vascular function
Endothelial-dependent and -independent vascular function will be assessed by venous occlusion plethysmography
Time frame: Baseline and 12 weeks
Maximal oxygen consumption
Maximal oxygen consumption will be collected breath-by-breath using a silicone mask (Hans Rudolph®, Shawnee, USA) connected to an Ultima CardiO2 metabolic cart (Medical Graphics®, Saint Louis, USA).
Time frame: Baseline and 12 weeks
Plan to share: No — Unnamed data collected and research results will be stored in a cloud-based system (Dropbox) and may be accessed after permission granted by the principal investigator.
Started Oct 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.
Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 26 months is below that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Instituto Nacional de Cardiologia de Laranjeiras